Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.

Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R.

Leukemia. 2007 Mar;21(3):529-34. Epub 2007 Jan 18.

PMID:
17230230
2.

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Stewart AK, Fonseca R.

J Clin Oncol. 2005 Sep 10;23(26):6339-44. Review.

PMID:
16155017
3.

Myeloma: classification and risk assessment.

Fonseca R, Monge J.

Semin Oncol. 2013 Oct;40(5):554-66. doi: 10.1053/j.seminoncol.2013.07.002. Review.

PMID:
24135400
4.

Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach.

Fonseca R, Stewart AK.

Mol Cancer Ther. 2007 Mar;6(3):802-10. Review.

5.

Review of molecular diagnostics in multiple myeloma.

Stewart AK, Fonseca R.

Expert Rev Mol Diagn. 2007 Jul;7(4):453-9. Review.

PMID:
17620051
6.

Risk stratification in the era of novel therapies.

San-Miguel J, Mateos MV, Gutierrez NC.

Cancer J. 2009 Nov-Dec;15(6):457-64. doi: 10.1097/PPO.0b013e3181c51efa. Review.

PMID:
20010164
7.

Prognostic impact of cytogenetic aberrations in patients with multiple myeloma or monoclonal gammopathy of unknown significance.

Schilling G, Dierlamm J, Hossfeld DK.

Hematol Oncol. 2005 Sep-Dec;23(3-4):102-7. Review.

PMID:
16342296
8.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

PMID:
15561686
9.

How to use new biology to guide therapy in multiple myeloma.

Morgan GJ, Kaiser MF.

Hematology Am Soc Hematol Educ Program. 2012;2012:342-9. doi: 10.1182/asheducation-2012.1.342. Review.

PMID:
23233602
10.

Clinical implications of chromosomal abnormalities in multiple myeloma.

Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA.

Leuk Lymphoma. 2006 May;47(5):803-14. Review.

PMID:
16753864
11.

Treatment of myeloma.

Smith ML, Newland AC.

QJM. 1999 Jan;92(1):11-4. Review.

12.

Many multiple myelomas: making more of the molecular mayhem.

Chesi M, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2011;2011:344-53. doi: 10.1182/asheducation-2011.1.344. Review.

13.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
14.

Update on risk stratification and treatment of newly diagnosed multiple myeloma.

Kapoor P, Rajkumar SV.

Int J Hematol. 2011 Oct;94(4):310-20. doi: 10.1007/s12185-011-0947-z. Epub 2011 Oct 18. Review.

PMID:
22005834
15.

Strategies for risk-adapted therapy in myeloma.

Fonseca R.

Hematology Am Soc Hematol Educ Program. 2007:304-10. Review.

PMID:
18024644
16.

From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Landgren O, Kyle RA, Rajkumar SV.

Clin Cancer Res. 2011 Mar 15;17(6):1243-52. doi: 10.1158/1078-0432.CCR-10-1822. Review.

17.

Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients.

Fassas AB, Tricot G.

Leuk Lymphoma. 2004 Jun;45(6):1083-91. Review.

PMID:
15359986
18.

Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.

Bazzi M, Badros A.

Cancer Biol Ther. 2010 Nov 1;10(9):830-8. Epub 2010 Nov 1. Review.

PMID:
21045554
19.

Identification and validation of novel therapeutic targets for multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Anderson KC.

J Clin Oncol. 2005 Sep 10;23(26):6345-50. Review.

PMID:
16155018
20.
Items per page

Supplemental Content

Write to the Help Desk